Kwality Pharmaceuticals Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Kwality Pharmaceuticals Ltd is ₹ 2497 as of 12 Jun 15:30 . The P/E Ratio of Kwality Pharmaceuticals Ltd changed from 3.8 on March 2021 to 22.6 on March 2025 . This represents a CAGR of 42.84% over 5 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 years The Market Cap of Kwality Pharmaceuticals Ltd changed from ₹ 58.11 crore on March 2021 to ₹ 901.74 crore on March 2025 . This represents a CAGR of 73.05% over 5 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 years The revenue of Kwality Pharmaceuticals Ltd for the Mar '26 is ₹ 158.17 crore as compare to the Dec '25 revenue of ₹ 123.97 crore. This represent the growth of 27.59% The revenue of Medicamen Biotech Ltd for the Mar '26 is ₹ 62.38 crore as compare to the Dec '25 revenue of ₹ 47.44 crore. This represent the growth of 31.49% The ebitda of Kwality Pharmaceuticals Ltd for the Mar '26 is ₹ 39.82 crore as compare to the Dec '25 ebitda of ₹ 29.65 crore. This represent the growth of 34.3% The ebitda of Medicamen Biotech Ltd for the Mar '26 is ₹ 7.18 crore as compare to the Dec '25 ebitda of ₹ 4.91 crore. This represent the growth of 46.23% The net profit of Kwality Pharmaceuticals Ltd changed from ₹ 8.35 crore to ₹ 25.31 crore over 8 quarters. This represents a CAGR of 74.10% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 4.45 crore over 8 quarters. This represents a CAGR of 135.85% The Dividend Payout of Kwality Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 years .

About Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Limited was Incorporated on May 4th 1983 when its founder Mr. Ramesh Arora was inspired to begin his own venture leaving behind the already flourishing family business of spinning and aromatics.
With little background of finished pharmaceuticals and high held spirits and will, he started this business.
He received his first drug license in 1981 approved for liquid oral manufacturing.
Presently, the Company has 56 different sections available at their production centres. Kwality Pharmaceuticals Ltd. are manufacturer of finished pharmaceutical formulations in a Liquid Orals, Dry Syrups, Tablets, Capsules, Sterile Powder for Injections and small volume injectables.
The Company has the most modern & sophisticated Plant, Equipment, technique, and workforce.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of Kwality Pharmaceuticals Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Kwality Pharmaceuticals Ltd or Medicamen Biotech Ltd?

Market cap of Kwality Pharmaceuticals Ltd is 2,590 Cr while Market cap of Medicamen Biotech Ltd is 311 Cr

What are the key factors driving the stock performance of Kwality Pharmaceuticals Ltd and Medicamen Biotech Ltd?

The stock performance of Kwality Pharmaceuticals Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kwality Pharmaceuticals Ltd and Medicamen Biotech Ltd?

As of June 15, 2026, the Kwality Pharmaceuticals Ltd stock price is INR ₹2497.0. On the other hand, Medicamen Biotech Ltd stock price is INR ₹229.45.

How do dividend payouts of Kwality Pharmaceuticals Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Kwality Pharmaceuticals Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.